33 results
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
[2] https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Prolia/prolia_pi.pdf
[3] https://www.janssenlabels.com/package-insert
6-K
EX-99.1
ALVO
Alvotech
25 Apr 24
Current report (foreign)
12:36pm
and is not claimed.
Sources
[1] Data from Evaluate Pharma.
[2] https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SIMPONI-pi.pdf
6-K
EX-99.1
ALVO
Alvotech
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Prolia/prolia_pi.pdf
[6] https://www.janssenlabels.com/package-insert/product-monograph/prescribing
6-K
EX-99.1
ALVO
Alvotech
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
of intellectual-property rights in July 2024
Approval for the Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical … authorization application for AVT04, based on a comprehensive package of analytical and clinical data. This included data from the AVT04-GL-301 confirmatory
6-K/A
EX-99.1
zcpww8gf1khb1bil18
30 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
9:19am
6-K
EX-99.1
7vf 4gg3s1ilutct
29 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
i0ha4hrr
29 Nov 23
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
7:00am
6-K
EX-99.1
eb6vvrtd2
13 Nov 23
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
6:15am
6-K
EX-99.1
2keijj ldcagsa
12 Oct 23
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
9:00am
6-K
EX-99.1
x1fdariu
25 Sep 23
Current report (foreign)
4:30pm
6-K
EX-99.8
gifwf2nu
31 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.1
t6ov7cjjv 9y7bj
24 Jul 23
Provide Update on Strategic Biosimilars Partnership
4:15pm
6-K
EX-99.1
88y55xnetlyrs0p yiga
13 Jun 23
Current report (foreign)
8:12am
424B3
gc61ovgi4 1bs
21 Sep 22
Prospectus supplement
4:59pm
424B3
4h5ll2
21 Sep 22
Prospectus supplement
4:54pm
F-1/A
cd7ke wm6cx1h4y
14 Sep 22
Registration statement (foreign) (amended)
4:58pm
F-1/A
wu1cr2q11lfmtow
13 Sep 22
Registration statement (foreign) (amended)
5:19pm
F-1/A
gv7dp08
27 Jul 22
Registration statement (foreign) (amended)
5:13pm
F-1
jxn2ilbuj3xyldujf9i
22 Jul 22
Registration statement (foreign)
4:42pm